PET accurately identifies esophageal cancer patients' positive responses to chemotherapyJune 04, 2007Molecular imaging opens door to tailoring treatment based on cancer tumor biology, report researchers at SNM's 54th Annual Meeting June 2-6 in Washington, D.C. WASHINGTON, D.C.-Early metabolic imaging with positron emission tomography (PET) accurately identifies patients responding to chemotherapy for esophageal cancer, noted German researchers at the 54th Annual Meeting of SNM, the world's largest society for molecular imaging and nuclear medicine professionals. "This is the first study to apply PET results from early metabolic response assessment to clinical decision making in the treatment of common solid tumors," said Ken Herrmann, a resident in the department of nuclear medicine at Technical University in Munich, Germany. "The outcome for metabolic responders turned out to be remarkably favorable compared to metabolic non-responders. Our results show that PET helps select patients who are benefiting from chemotherapy," he noted. "Based on our early response assessment, the course is set for tailoring multimodality treatment on the basis of tumor biology," explained Herrmann. In addition, PET-response-guided treatment "helped circumvent the administration of inefficient chemotherapy to patients with no metabolic response-without compromising their outcome," added Herrmann. Less well-known than lung cancer-but no less serious-esophageal cancer starts in the inner layer of the esophagus, the 10-inch long tube that connects your throat and stomach. Adenocarcinoma is esophageal cancer that begins in cells that make and release mucus and other fluids. In this country, more than 14,000 persons are expected to die from the disease, and more than 15,000 new cases will be diagnosed this year. The MUNICON trial, conducted from May 2003 through August 2005, was the first study conducted to apply PET results from early metabolic response assessment to clinical decision-making in the treatment of common solid tumors, said Herrmann. "This clinical trial delineated how response-guided treatment algorithms may be applied to clinical practice, serving as a model for other malignant diseases-like lung, head and neck or ovarian cancer-and providing information to alter treatment and patient management," he explained. "The results of our study delineate how response-guided treatment algorithms can be applied in clinical practice in the future," said Herrmann. PET is a powerful medical imaging procedure that noninvasively demonstrates the function of organs and tissues. When PET is used to image cancer, a radiopharmaceutical (such as fluorodeoxyglucose or FDG, which which is a radioactive analog of sugar) is injected into the vein of a patient. Cancer cells metabolize sugar at higher rates than normal cells, and the radiopharmaceutical is taken up in higher concentrations to cancerous areas. PET scans show where FDG is by tracking photons given off by the radioactive tracer. PET scanning provides information at a molecular level-not available through other procedures-about the body's chemistry, metabolic activity and body function. Society of Nuclear Medicine |
|||||||||||||||||||||
| Related Esophageal Cancer Current Events and Esophageal Cancer News Articles Reflux esophagitis due to immune reaction, not acute acid burn, UT Southwestern researchers report Contrary to current thinking, a condition called gastroesophageal reflux disease (GERD) might not develop as a direct result of acidic digestive juices burning the esophagus, UT Southwestern Medical Center researchers have found in an animal study. African-Americans with colorectal cancer have poorer outcomes, lower survival rates New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans. Surgeons at Boston Medical Center offering new procedure for acid reflux/GERD Boston Medical Center (BMC) surgeons are now offering patients an incisionless alternative to laparoscopic and traditional surgery for treatment of acid reflux or GERD. Barrett's esophagus patients have same survival rates as general population New Mayo Clinic research has found that survival rates of patients with Barrett's esophagus, which can be a precursor for esophageal cancer, are no different than the survival rates for the general population. GERD negatively impacts sleep quality, results in considerable economic burden There has been much debate about the relationship between gastroesophageal reflux disease (GERD) and sleep. Heavy drinkers face significantly increased cancer risk Heavy drinkers of beer and spirits face a much higher risk of developing cancer than the population at large, says a group of Montreal epidemiologists and cancer researchers. University of Saskatchewan and Canadian Synchrotron researchers shed light on esophageal disease Canadian Light Source (CLS) staff scientist Luca Quaroni and Dr. Alan Casson, Head of the Department of Surgery at the University of Saskatchewan (U of S) used the synchrotron's infrared microscope to identify tissue afflicted with a condition known as Barrett's Esophagus from chemical fingerprints associated with the disease, which can lead to esophageal cancer. NEJM study finds radiofrequency ablation can reverse Barrett's esophagus, reduce cancer risk Patients who have gastroesophageal reflux disease (GERD) for a prolonged period have an increased risk of developing Barrett's esophagus, a pre-cancerous condition where the tissue lining the esophagus becomes damaged by stomach acid and transformed into something like the inside of the stomach. Technique eradicates problems in most patients with Barrett's esophagus A procedure that uses heat generated by radio waves to treat Barrett's esophagus, a condition caused by acid reflux (severe heartburn), can eliminate signs of the potentially cancer-causing disorder and reduce the risk that the disease will progress. Study examines reliability of clinical and pathological diagnoses of Barrett's esophagus In a review of more than 2,000 patients coded for Barrett's esophagus, electronic diagnosis overestimated the prevalence of the disease according to researchers in California. More Esophageal Cancer Current Events and Esophageal Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||